<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Richards AR</submitter><funding>NCI NIH HHS</funding><funding>NIH</funding><funding>NIH HHS</funding><pagination>24</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12879400</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>18(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Protein EpiScores are a novel class of DNA methylation (DNAm)-based metrics proposed to measure peripheral immune system characteristics. Although Protein EpiScores have been associated with chronic disease risk, their relationship with colorectal cancer (CRC) survival has not been investigated.&lt;h4>Methods&lt;/h4>We generated new genome-wide DNAm data on pre-treatment whole blood samples from a case-control sample of 136 newly diagnosed CRC patients nested in the ColoCare Study and calculated 107 Protein EpiScores using the developer's algorithm. Over a median follow-up of 7.3 years (range: 0.3-13.8 years), 35 (26%) patients experienced disease recurrence, and 47 (35%) died. Protein EpiScore associations with disease-free and overall survival were tested using Cox regressio</pubmed_abstract><journal>Clinical epigenetics</journal><pubmed_title>Blood DNA methylation-predicted plasma protein levels and colorectal cancer survival.</pubmed_title><pmcid>PMC12879400</pmcid><funding_grant_id>P30-CA076292</funding_grant_id><funding_grant_id>P30 CA076292</funding_grant_id><pubmed_authors>Dowling BI</pubmed_authors><pubmed_authors>Toriola AT</pubmed_authors><pubmed_authors>Gigic B</pubmed_authors><pubmed_authors>Kresovich JK</pubmed_authors><pubmed_authors>Shibata D</pubmed_authors><pubmed_authors>Siegel EM</pubmed_authors><pubmed_authors>Jean-Baptiste E</pubmed_authors><pubmed_authors>Gomez MF</pubmed_authors><pubmed_authors>Stewart PA</pubmed_authors><pubmed_authors>Figueiredo JC</pubmed_authors><pubmed_authors>Li CI</pubmed_authors><pubmed_authors>Richards AR</pubmed_authors><pubmed_authors>Ulrich CM</pubmed_authors><pubmed_authors>Byrd DA</pubmed_authors></additional><is_claimable>false</is_claimable><name>Blood DNA methylation-predicted plasma protein levels and colorectal cancer survival.</name><description>&lt;h4>Background&lt;/h4>Protein EpiScores are a novel class of DNA methylation (DNAm)-based metrics proposed to measure peripheral immune system characteristics. Although Protein EpiScores have been associated with chronic disease risk, their relationship with colorectal cancer (CRC) survival has not been investigated.&lt;h4>Methods&lt;/h4>We generated new genome-wide DNAm data on pre-treatment whole blood samples from a case-control sample of 136 newly diagnosed CRC patients nested in the ColoCare Study and calculated 107 Protein EpiScores using the developer's algorithm. Over a median follow-up of 7.3 years (range: 0.3-13.8 years), 35 (26%) patients experienced disease recurrence, and 47 (35%) died. Protein EpiScore associations with disease-free and overall survival were tested using Cox regressio</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Feb</publication><modification>2026-07-15T13:17:21.172Z</modification><creation>2026-07-05T03:08:20.328Z</creation></dates><accession>S-EPMC12879400</accession><cross_references><pubmed>41622289</pubmed><doi>10.1186/s13148-026-02059-3</doi></cross_references></HashMap>